Marksans Pharma Limited
Marksans Pharma Limited (MARKSANS.NS) Stock Competitors & Peer Comparison
See (MARKSANS.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MARKSANS.NS | ₹175.86 | +1.03% | 79.7B | 22.15 | ₹7.94 | +0.46% |
| CIPLA.BO | ₹1,345.70 | +1.46% | 1.1T | 24.00 | ₹56.20 | +1.21% |
| CIPLA.NS | ₹1,346.10 | +1.46% | 1.1T | 23.93 | ₹56.25 | +1.21% |
| ABBOTINDIA.BO | ₹26,413.10 | +0.27% | 561.3B | 37.18 | ₹710.49 | +1.80% |
| ABBOTINDIA.NS | ₹26,410.00 | +0.17% | 561.2B | 36.83 | ₹717.13 | +1.80% |
| GLAXO.NS | ₹2,652.50 | +1.31% | 449.3B | 44.09 | ₹60.16 | +2.06% |
| GLAXO.BO | ₹2,650.85 | +1.20% | 449.1B | 47.08 | ₹56.30 | +2.06% |
| GLAND.NS | ₹1,848.50 | +2.56% | 304.6B | 35.98 | ₹51.37 | +1.00% |
| GLAND.BO | ₹1,845.60 | +2.46% | 304.1B | 35.95 | ₹51.34 | +1.00% |
| PFIZER.NS | ₹5,146.20 | +1.21% | 235.4B | 27.57 | ₹186.63 | +3.25% |
Stock Comparison
MARKSANS.NS vs CIPLA.BO Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, CIPLA.BO has a market cap of 1.1T. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while CIPLA.BO trades at ₹1,345.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas CIPLA.BO's P/E ratio is 24.00. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to CIPLA.BO's ROE of +0.15%. Regarding short-term risk, MARKSANS.NS is less volatile compared to CIPLA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MARKSANS.NS.Check CIPLA.BO's competition here
MARKSANS.NS vs CIPLA.NS Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, CIPLA.NS has a market cap of 1.1T. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while CIPLA.NS trades at ₹1,346.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas CIPLA.NS's P/E ratio is 23.93. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to CIPLA.NS's ROE of +0.15%. Regarding short-term risk, MARKSANS.NS is less volatile compared to CIPLA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MARKSANS.NS.Check CIPLA.NS's competition here
MARKSANS.NS vs ABBOTINDIA.BO Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, ABBOTINDIA.BO has a market cap of 561.3B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while ABBOTINDIA.BO trades at ₹26,413.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas ABBOTINDIA.BO's P/E ratio is 37.18. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to ABBOTINDIA.BO's ROE of +0.38%. Regarding short-term risk, MARKSANS.NS is more volatile compared to ABBOTINDIA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MARKSANS.NS.Check ABBOTINDIA.BO's competition here
MARKSANS.NS vs ABBOTINDIA.NS Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, ABBOTINDIA.NS has a market cap of 561.2B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while ABBOTINDIA.NS trades at ₹26,410.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas ABBOTINDIA.NS's P/E ratio is 36.83. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to ABBOTINDIA.NS's ROE of +0.38%. Regarding short-term risk, MARKSANS.NS is more volatile compared to ABBOTINDIA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MARKSANS.NS.Check ABBOTINDIA.NS's competition here
MARKSANS.NS vs GLAXO.NS Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, GLAXO.NS has a market cap of 449.3B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while GLAXO.NS trades at ₹2,652.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas GLAXO.NS's P/E ratio is 44.09. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to GLAXO.NS's ROE of +0.56%. Regarding short-term risk, MARKSANS.NS is less volatile compared to GLAXO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MARKSANS.NS.Check GLAXO.NS's competition here
MARKSANS.NS vs GLAXO.BO Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, GLAXO.BO has a market cap of 449.1B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while GLAXO.BO trades at ₹2,650.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas GLAXO.BO's P/E ratio is 47.08. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to GLAXO.BO's ROE of +0.56%. Regarding short-term risk, MARKSANS.NS is less volatile compared to GLAXO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MARKSANS.NS.Check GLAXO.BO's competition here
MARKSANS.NS vs GLAND.NS Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, GLAND.NS has a market cap of 304.6B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while GLAND.NS trades at ₹1,848.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas GLAND.NS's P/E ratio is 35.98. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to GLAND.NS's ROE of +0.09%. Regarding short-term risk, MARKSANS.NS is less volatile compared to GLAND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MARKSANS.NS.Check GLAND.NS's competition here
MARKSANS.NS vs GLAND.BO Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, GLAND.BO has a market cap of 304.1B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while GLAND.BO trades at ₹1,845.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas GLAND.BO's P/E ratio is 35.95. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to GLAND.BO's ROE of +0.09%. Regarding short-term risk, MARKSANS.NS is less volatile compared to GLAND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MARKSANS.NS.Check GLAND.BO's competition here
MARKSANS.NS vs PFIZER.NS Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, PFIZER.NS has a market cap of 235.4B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while PFIZER.NS trades at ₹5,146.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas PFIZER.NS's P/E ratio is 27.57. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to PFIZER.NS's ROE of +0.21%. Regarding short-term risk, MARKSANS.NS is less volatile compared to PFIZER.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MARKSANS.NS.Check PFIZER.NS's competition here
MARKSANS.NS vs PFIZER.BO Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, PFIZER.BO has a market cap of 235.3B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while PFIZER.BO trades at ₹5,144.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas PFIZER.BO's P/E ratio is 28.06. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to PFIZER.BO's ROE of +0.21%. Regarding short-term risk, MARKSANS.NS is less volatile compared to PFIZER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MARKSANS.NS.Check PFIZER.BO's competition here
MARKSANS.NS vs SANOFI.BO Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, SANOFI.BO has a market cap of 95.4B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while SANOFI.BO trades at ₹4,142.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas SANOFI.BO's P/E ratio is 26.81. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to SANOFI.BO's ROE of +0.42%. Regarding short-term risk, MARKSANS.NS is more volatile compared to SANOFI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MARKSANS.NS.Check SANOFI.BO's competition here
MARKSANS.NS vs SANOFI.NS Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, SANOFI.NS has a market cap of 95.2B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while SANOFI.NS trades at ₹4,134.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas SANOFI.NS's P/E ratio is 26.73. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to SANOFI.NS's ROE of +0.42%. Regarding short-term risk, MARKSANS.NS is more volatile compared to SANOFI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for MARKSANS.NS.Check SANOFI.NS's competition here
MARKSANS.NS vs SANOFICONR.NS Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, SANOFICONR.NS has a market cap of 92.3B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while SANOFICONR.NS trades at ₹4,009.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas SANOFICONR.NS's P/E ratio is 42.40. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to SANOFICONR.NS's ROE of +0.82%. Regarding short-term risk, MARKSANS.NS is less volatile compared to SANOFICONR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MARKSANS.NS.Check SANOFICONR.NS's competition here
MARKSANS.NS vs MARKSANS.BO Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, MARKSANS.BO has a market cap of 79.5B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while MARKSANS.BO trades at ₹175.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas MARKSANS.BO's P/E ratio is 22.62. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to MARKSANS.BO's ROE of +0.14%. Regarding short-term risk, MARKSANS.NS is more volatile compared to MARKSANS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for MARKSANS.NS.Check MARKSANS.BO's competition here
MARKSANS.NS vs SMSPHARMA.BO Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, SMSPHARMA.BO has a market cap of 35.7B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while SMSPHARMA.BO trades at ₹381.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas SMSPHARMA.BO's P/E ratio is 38.05. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to SMSPHARMA.BO's ROE of +0.14%. Regarding short-term risk, MARKSANS.NS is less volatile compared to SMSPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MARKSANS.NS.Check SMSPHARMA.BO's competition here
MARKSANS.NS vs SMSPHARMA.NS Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, SMSPHARMA.NS has a market cap of 35.7B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while SMSPHARMA.NS trades at ₹380.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas SMSPHARMA.NS's P/E ratio is 38.01. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to SMSPHARMA.NS's ROE of +0.14%. Regarding short-term risk, MARKSANS.NS is less volatile compared to SMSPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MARKSANS.NS.Check SMSPHARMA.NS's competition here
MARKSANS.NS vs SENORES.NS Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, SENORES.NS has a market cap of 35.6B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while SENORES.NS trades at ₹772.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas SENORES.NS's P/E ratio is 30.04. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to SENORES.NS's ROE of +0.13%. Regarding short-term risk, MARKSANS.NS is less volatile compared to SENORES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MARKSANS.NS.Check SENORES.NS's competition here
MARKSANS.NS vs NGLFINE.NS Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, NGLFINE.NS has a market cap of 13.9B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while NGLFINE.NS trades at ₹2,242.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas NGLFINE.NS's P/E ratio is 39.23. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to NGLFINE.NS's ROE of +0.12%. Regarding short-term risk, MARKSANS.NS is less volatile compared to NGLFINE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MARKSANS.NS.Check NGLFINE.NS's competition here
MARKSANS.NS vs NGLFINE.BO Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, NGLFINE.BO has a market cap of 13.8B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while NGLFINE.BO trades at ₹2,230.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas NGLFINE.BO's P/E ratio is 38.89. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to NGLFINE.BO's ROE of +0.12%. Regarding short-term risk, MARKSANS.NS is less volatile compared to NGLFINE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MARKSANS.NS.Check NGLFINE.BO's competition here
MARKSANS.NS vs TTKHLTCARE.NS Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, TTKHLTCARE.NS has a market cap of 12.9B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while TTKHLTCARE.NS trades at ₹915.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas TTKHLTCARE.NS's P/E ratio is 21.53. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to TTKHLTCARE.NS's ROE of +0.06%. Regarding short-term risk, MARKSANS.NS is less volatile compared to TTKHLTCARE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MARKSANS.NS.Check TTKHLTCARE.NS's competition here
MARKSANS.NS vs KOPRAN.NS Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, KOPRAN.NS has a market cap of 6.3B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while KOPRAN.NS trades at ₹129.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas KOPRAN.NS's P/E ratio is 37.94. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to KOPRAN.NS's ROE of +0.03%. Regarding short-term risk, MARKSANS.NS is less volatile compared to KOPRAN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for MARKSANS.NS.Check KOPRAN.NS's competition here
MARKSANS.NS vs KOPRAN.BO Comparison February 2026
MARKSANS.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MARKSANS.NS stands at 79.7B. In comparison, KOPRAN.BO has a market cap of 6.3B. Regarding current trading prices, MARKSANS.NS is priced at ₹175.86, while KOPRAN.BO trades at ₹129.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MARKSANS.NS currently has a P/E ratio of 22.15, whereas KOPRAN.BO's P/E ratio is 37.94. In terms of profitability, MARKSANS.NS's ROE is +0.14%, compared to KOPRAN.BO's ROE of +0.03%. Regarding short-term risk, MARKSANS.NS is less volatile compared to KOPRAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for MARKSANS.NS.Check KOPRAN.BO's competition here